EGLE-THERAPEUTICS
5.5.2022 11:02:13 CEST | Business Wire | Press release
Egle Therapeutics SAS (Egle), an emerging biotechnology company dedicated to developing novel immunotherapies for oncology and autoimmune diseases, is pleased to announce Pierre Legault as Chairman and board member as of March 2022. With extensive experience over 35 years in leadership roles at leading companies across the biotech and pharmaceutical sector, Mr. Legault will be a key part of the team as Egle deploys its first-in-class technology platforms to construct a drug pipeline of novel immunotherapies targeting suppressor regulatory T cells (Tregs).
“We’re delighted to welcome Pierre Legault as Chairman and board member of Egle. His depth and breadth of experience will be of great value to us in accelerating Egle’s strategic path forward,” commented entrepreneur Luc Boblet, Co-Founder and CEO of Egle. “Mr. Legault’s professional portfolio will complement our dynamic team as we progress Egle’s mission as a game changer in the field of modulating regulatory T-cells to treat cancer and autoimmune diseases.”
Mr. Pierre Legault, Chairman of the Board of Directors at Egle said, “Egle’s innovative technology platform is an exciting prospect in the field of immunotherapy. I look forward to working with the team to construct a drug pipeline that is committed to improving the health of patients.”
Over the past 5 years, Mr. Legault has been at the cutting-edge of innovative oncology therapeutics, serving as Director of Syndax Pharmaceuticals, and Chairman of the Board at Artios Pharma, Bicycle Therapeutics, and Sitryx Therapeutics. This first-hand experience of wide-ranging novel approaches to treat cancer and autoimmune conditions places Mr. Legault in a very strong position as he joins the team at Egle Therapeutics.
In his early career, Mr. Legault held global roles including President, CEO and CFO at legacy companies of the Sanofi-Aventis group. Over the past decades, Mr. Legault has continued to build a rich profile of experience, holding C-suite executive roles and serving as a board member at over 20 pharmaceutical and biotechnology companies such as Prosidion Ltd., NPS, Armo, Clementia, Poxel, Amolyt Pharma, Urovant Sciences and others.
Notes to Editors
About Egle Therapeutics SAS (Egle)
Established in early 2020 as a spin-out of Institut Curie by Luc Boblet, serial biotech entrepreneur, and Dr Eliane Piaggio, PhD, renowned immunologist in the Treg / IL-2 field (INSERM Research Director, Head of the Translational Immunotherapy Team – TransImm – at Institut Curie), Egle Therapeutics develops First-In-Class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. The key element of Egle’s core approach is the leveraging of its translational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed immunocytokines acting as antagonists or as selective Treg-agonists. Find out more at www.egle-tx.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220505005107/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom